Mads Lillevang-Johansen

Mads Lillevang-Johansen

Auto-generated profile, based on publicly available information

Mads Lillevang-Johansen

Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in Thyroid®
Verified
Journal Article
Closed access
MLMads Lillevang-Johansen
Mads Lillevang-Johansen
BABo Abrahamsen
Bo Abrahamsen
HJHenrik Jørgensen
Henrik Jørgensen
TBThomas Heiberg Brix
Thomas Heiberg Brix
LHLaszlo Hegedüs
Laszlo Hegedüs
Objective To investigate the association between hypothyroidism and mortality in both treated and untreated hypothyroid patients, and the consequences of over- and undertreatment with respect to mortality. Patients and methods Register-based cohort study of 235 168 individuals who had at least one serum TSH during 1995 to 2011 (median follow-up, 7.2 years). Hypothyroidism was defined as at least two measurements of TSH>4.0 mIU/L within a half year spaced by at least 14 days, or one measurement of TSH>4.0 mIU/L and two filled prescriptions of levothyroxine the following year. All-cause mortality rates were calculated using multivariable Cox regression analysis adjusted for age, gender and comorbidities, using the Charlson Comorbidity Index. Results Mortality was increased in untreated hypothyroid individuals (n=673) [HR 1.46 (95% Confidence Interval (CI), 1.26 to 1.69; p4.0 mIU/L and ≤10 mIU/L, p10 mIU/L, p=0.002). Mortality was increased in both treated and untreated hypothyroid individuals for each six months a patient had increased TSH [HR 1.05 (95% CI, 1.02 to 1.07; p<0.0001) and HR 1.05 (95% CI, 1.02 to 1.07; p=0.0009), respectively]. In patients who received levothyroxine, HR for mortality increased by a factor 1.18 (95% CI, 1.15 to 1.21; p<0.0001) for each six months a patient exhibited decreased TSH. This finding was essentially unchanged after stratification by disease severity (mild or marked hypothyroidism) and age (above and below 65 years). Conclusion Mortality was increased in untreated, but not in treated hypothyroid individuals, independently of age and severity of hypothyroidism. Duration of decreased TSH in treated individuals had a greater impact on mortality than did duration of elevated TSH. These results stress the need for close monitoring of treatment in individuals receiving thyroid hormone replacement therapy.

1 June 2019 in European Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
MLMads Lillevang-Johansen
Mads Lillevang-Johansen
BABo Abrahamsen
Bo Abrahamsen
HJHenrik Jørgensen
Henrik Jørgensen
TBThomas Heiberg Brix
Thomas Heiberg Brix
LHLaszlo Hegedüs
Laszlo Hegedüs
Objective: To investigate the association between hypothyroidism and cardiovascular disease (CVD) in both treated and untreated hypothyroid patients, and the consequences of over- and under-treatment with respect to cardiovascular risk.Design: A registry-based case–control study nested within a population-based cohort of 275 467 individuals with at least one serum thyroid stimulating hormone (TSH) measurement in the period of 1995–2011.Methods: Incident cases of CVD were matched with controls according to gender, age and year of birth. Conditional logistic regression analyses were performed to calculate CVD risks associated with exposure to hypothyroidism, with adjustment for 19 pre-existing comorbidities, including cardiovascular disease and diabetes, using the Charlson Comorbidity Index.Results: Overall, 20 487 individuals experienced CVD (9.4%, incidence rate 13.1 per 1000 person-years, 95% confidence interval (CI), 13.0–13.3). Risk of CVD was increased in untreated hypothyroidism compared to euthyroidism (odds ratio (OR): 1.83 (95% CI: 1.43–2.35;P < 0.001)). Cardiovascular risk was increased in both treated and untreated hypothyroid individuals per half year of elevated TSH (OR: 1.11 (95% CI: 1.06–1.16;P < 0.001) and OR: 1.15 (95% CI: 1.09–1.23;P = 0.001), respectively). In patients treated with levothyroxine, OR for CVD was 1.12 (95% CI: 1.06–1.18;P < 0.001) for each 6 months of decreased TSH.Conclusion: Cardiovascular risk is increased in untreated, but not in treated hypothyroid patients. Among those with treated hypothyroidism, duration of decreased TSH (overtreatment) had a similar impact on cardiovascular risk as duration of elevated TSH (under-treatment), highlighting the importance of initiating treatment and maintaining biochemical euthyroidism in hypothyroid patients in order to reduce the risk of CVD and death.

28 March 2017 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
MLMads Lillevang-Johansen
Mads Lillevang-Johansen
BABo Abrahamsen
Bo Abrahamsen
HJHenrik Jørgensen
Henrik Jørgensen
TBThomas Heiberg Brix
Thomas Heiberg Brix
LHLaszlo Hegedüs
Laszlo Hegedüs
Introduction and Aim: Cumulative time-dependent excess mortality in hyperthyroid patients has been suggested. However, the effect of antithyroid treatment on mortality, especially in subclinical hyperthyroidism, remains unclarified. We investigated the association between hyperthyroidism and mortality in both treated and untreated hyperthyroid individuals. Patients and Methods: Register-based cohort study of 235,547 individuals who had at least one serum thyroid-stimulating hormone (TSH) measurement in the period 1995 to 2011 (7.3 years median follow-up). Hyperthyroidism was defined as at least two measurements of low serum TSH. Mortality rates for treated and untreated hyperthyroid subjects compared with euthyroid controls were calculated using multivariate Cox regression analyses, controlling for age, sex, and comorbidities. Cumulative periods of decreased serum TSH were analyzed as a time-dependent covariate. Results: Hazard ratio (HR) for mortality was increased in untreated [1.23; 95% confidence interval (CI), 1.12 to 1.37; P < 0.001], but not in treated, hyperthyroid patients. When including cumulative periods of TSH in the Cox regression analyses, HR for mortality per every 6 months of decreased TSH was 1.11 (95% CI, 1.09 to 1.13; P < 0.0001) in untreated hyperthyroid patients (n = 1137) and 1.13 (95% CI, 1.11 to 1.15; P < 0.0001) in treated patients (n = 1656). This corresponds to a 184% and 239% increase in mortality after 5 years of decreased TSH in untreated and treated hyperthyroidism, respectively. Conclusions: Mortality is increased in hyperthyroidism. Cumulative periods of decreased TSH increased mortality in both treated and untreated hyperthyroidism, implying that excess mortality may not be driven by lack of therapy, but rather inability to keep patients euthyroid. Meticulous follow-up during treatment to maintain biochemical euthyroidism may be warranted.

15 March 2019 in Thyroid®
Verified
Journal Article
Closed access
MLMads Lillevang-Johansen
Mads Lillevang-Johansen
BABo Abrahamsen
Bo Abrahamsen
HJHenrik Jørgensen
Henrik Jørgensen
TBThomas Heiberg Brix
Thomas Heiberg Brix
LHLaszlo Hegedüs
Laszlo Hegedüs
Background: Cardiovascular disease remains the most prevalent cause of death in hyperthyroidism. However, the impact on cardiovascular events of varying thyroid status and of treatment remains unclarified. The aims of this study were to investigate the association between hyperthyroidism and cardiovascular events in treated and untreated hyperthyroid individuals, as well as exploring the impact of cumulative periods of hyperthyroidism as a proxy for undertreatment on cardiovascular events. Method: This was a case-control study nested within a population-based cohort of individuals attending health services in Funen County, Denmark, in the period from 1995 to 2011. Data on comorbidities and mortality were collected from The Danish National Patient Register and The Danish Register of Causes of Death. Participants were 275,467 individuals with at least one serum thyrotropin (TSH) measurement in the study period. Hyperthyroidism was defined as at least two measurements of decreased serum TSH within six months, separated by at least 14 days. Incident cases of cardiovascular disease (myocardial infarction, atrial fibrillation, heart failure, stroke, and cardiovascular death) were matched with controls. Conditional logistic regression analyses were performed to calculate odds ratios (OR) for exposure to hyperthyroidism, adjusting for preexisting comorbidities. Results: A total of 20,651 individuals experienced a cardiovascular event (9.5% incidence rate 13.2/1000 person-years [confidence interval (CI) 13.0–13.4]) compared to euthyroid individuals, conditional logistic regression showed increased cardiovascular risk in untreated hyperthyroid patients (OR = 1.25 [CI 1.06–1.48], p = 0.007) but not in treated hyperthyroid patients (OR = 1.04 [CI 0.90–1.22], p = 0.57)]. The OR for cardiovascular events per six months of decreased TSH was 1.09 ([CI 1.05–1.14], p < 0.001) in treated hyperthyroid individuals, and 1.10 ([CI 1.05–1.15], p < 0.001) in untreated hyperthyroid individuals. Conclusions: The risk of cardiovascular disease was found to be increased in untreated hyperthyroid patients, and the duration of decreased TSH associated with increasing risk of cardiovascular outcomes in both treated and untreated hyperthyroid individuals. This suggests that increased cardiovascular risk is driven not only by lack of treatment but also by insufficient therapy. The results support timely treatment and careful monitoring of hyperthyroid patients in order to reduce cardiovascular risk.

30 May 2013 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
MLMads Lillevang‐Johansen
Mads Lillevang‐Johansen
IPInge Petersen
Inge Petersen
KCKaare Christensen
Kaare Christensen
LHLaszlo Hegedüs
Laszlo Hegedüs
TBThomas Heiberg Brix
Thomas Heiberg Brix

19 November 2024 in medRxiv
Verified
Preprint
Open access
PDF file
LBLaust Frisenberg Buhl
Laust Frisenberg Buhl
LCLouise Lehmann Christensen
Louise Lehmann Christensen
RHRikke Hjortebjerg
Rikke Hjortebjerg
SHSelma Hasific
Selma Hasific
CHClara Hjerrild
Clara Hjerrild
JFJan Frystyk
Jan Frystyk
Background: Illicit use of anabolic androgenic steroids (AAS) is common among recreational athletes, yet comprehensive studies on adverse cardiovascular outcomes, especially in female AAS users, are lacking. Methods: A cross-sectional study of recreational athletes of women and men was conducted, involving active and previous AAS users and non-users aged ≥18 years. Previous use was defined as discontinuation of AAS at least three months prior to study. Primary outcomes included atherosclerosis (carotid, femoral, and coronary artery plaques) and cardiac function, assessed using vascular ultrasound, coronary computed tomography angiography and echocardiography. Results: Median age was 36 years for active users (n=80, 19 women), 35 years for previous users (n=26, 8 women), and 40 years for non-users (n=58, 16 women) (p=NS). Median AAS usage period was 2.2 years for both active and previous users; the latter group had discontinued intake 2.5 years before study (range: 3 months to 29 years). There was no group differences when comparing the number of femoral/carotid artery plaques, the coronary artery calcium (CAC) score or the number of non-calcified plaques. However, confounder-adjusted logistic regression showed associations between cumulative AAS use and a positive CAC score (OR: 1.23, 95% CI: 1.09–1.39, p=0.001) and the presence of non-calcified plaque (OR: 1.17, 95% CI: 1.05–1.30, p=0.004), respectively, when comparing previous and ongoing users vs. non-users. These associations were also present in men, but not women. Moreover, >5 years of AAS use increased the fraction of athletes with increased severity of calcifications (p=0.043). Echocardiography showed that active AAS using males and females had impaired left ventricular global longitudinal strain (LVGLS) and right ventricular global longitudinal strain (RVGLS) compared to sex-matched non-users (p<0.001). Multivariable analysis showed that cumulative AAS use correlated with worsening of LVGLS (p=0.002) and RVGLS (p=0.001). Finally, after 5 years of cumulative AAS use, nearly all athletes had ventricular mass above and left ventricular ejection fraction below the median of normal range. Conclusion: In men, the cumulative lifetime AAS exposure was an independent predictor of coronary atherosclerosis. However, both male and female AAS users share risks of myocardial dysfunction, underscoring significant cardiovascular risks across genders. CLINICAL PERSPECTIVE: Key observations from the study: In recreational athletes, the accumulated lifetime AAS exposure associates with a higher prevalence of non-calcified plaques and coronary artery calcification in male recreational athletes. Our study suggests that more than 5 years of AAS use constitutes a threshold beyond which the development of coronary calcifications significantly increases compared to non-users. In addition to compromised left ventricular systolic and diastolic function, AAS users exhibited significantly reduced right ventricular function, indicating a biventricular cardiac impact of AAS. Male and female AAS users showed similar patterns of cardiac deterioration. These findings highlight the significant cardiovascular risks associated with AAS use in both male and female recreational athletes, underscoring the importance of targeted research, educational programs, information campaigns, and intervention strategies for this population, regardless of gender.